INTRODUCTION 23 24
Fungal infections continue to represent a serious challenge to human health, due partly to 25 interventions or other diseases that may facilitate fungal proliferation. Patients with 26 debilitating diseases such as HIV, organ transplant recipients, major burns patients and 27 those treated with corticosteroids or other immunosuppressants are more susceptible to 28 fungal infections. Among the most important opportunistic fungal pathogens are Candida 29 spp., the fourth most common cause of nosocomial infection with a case rate of 72.8 per 30 million people per year and a mortality rate close to 34% (1) . Other fungal genera that are 31 common pathogens include Aspergillus, Cryptococcus and Fusarium. Mortality rates are as 32 high as 62% (2). Drugs used to treat fungal infections include the polyenes, azoles and 33 echinocandins. However, with the limited number of antifungals available, newer 34 treatments are required. Recently, combination treatments with antifungals have attracted 35 considerable attention as a method of management, due to a paucity of newly emerging 36
agents. An advantage of such combinations is that they reduce the likelihood of resistance 37 (3). 38
One factor that helps in the development of novel antifungal entities or in 39 elucidating mode of action is that many fungal genome sequences are now available. 40
Certain fungi are also highly amenable to laboratory manipulation. Thus, the yeast 41
Saccharomyces cerevisiae has become broadly adopted as a eukaryotic cell model of 42
choice. The yeast model has been applied to characterize the actions of antifungal drugs 43 (4, 5) as well as a diverse range of other therapeutic compounds including antimalarial 44 drugs (6, 7). Antimalarials are notoriously poorly characterized, with regard both to their 45 modes of action against the malaria parasite and to the adverse reactions that many 46 provoke in humans. A screen of the yeast deletion strain collection against the antimalarial 47
The mannosylphosphate component of cell wall mannoprotein was determined with 130 alcian blue staining as described previously (22) . Cells were cultured with or without CQ 131 either overnight or for 3 h, until OD 600~1 .0. Samples (5 ml) were washed twice with 2 ml 132 0.02-M HCl and resuspended in 1 ml of 0.005% (w/v) alcian blue in 0.02 M HCl. The 133 mixture was left to stand at room temperature for 10 min, then centrifuged for 3 min at 134 18,000 g. Unbound alcian blue was determined from OD 600 of the supernatant, with 135 reference to a standard curve prepared with alcian blue solutions ranging from 0 to 0.05% 136 (w/v) in 0.02 M HCl. The amount of alcian blue bound to cells was then calculated by 137 subtracting the amount of unbound dye from the starting amount of 50 µg alcian blue. 138
The chitin content of cell walls was probed with calcoflour white (23). Cells were 139 cultured with or without CQ either overnight or for 3 h, then adjusted to 1 x 10 6 CFU ml -1 , 140
washed twice with PBS and stained with 1.1 µM calcofluor white for 30 min. Stained cells 141
were washed and resuspended in 1 ml PBS. Calcofluor white fluorescence was quantified 142 with a Becton Dickinson LSR Flow II flow cytometer, equipped with a 365nm laser. 143
Calcofluor white was detected with a 440/40BP emission filter. 144
145
Chloroquine uptake. Chloroquine uptake by cells was estimated using a 146 fluorescently-labelled chloroquine molecule, LynxTag-CQ™ Green (BioLynx Technologies). 147
Aliquots (100 µl) of cells grown to OD 600~2 .0 in YEPD broth were transferred to microfuge 148 tubes. Chloroquine was added together with 2 µl of 1-mM LynxTag-CQ™ and, where 149 specified, caffeine. Cells were incubated in the dark with shaking at 30ºC. Samples (10 µl) 150 were removed at intervals and cells washed and resuspended in a 1:100 dilution of PBS. 151
Fluorescence from cellular LynxTag-CQ™ Green was measured with a Becton Dickinson 152
FACSCanto flow cytometer, with excitation at 488 nm and emission detected through a 153 505LP, 530/30BP filter. A 10 µl sample was also washed and examined with a 100X oil 154 immersion lens and appropriate filters to confirm the presence of CQ within yeast cells.
RESULTS 156 157
Deletion strains with altered chloroquine resistance. The yeast homozygous diploid 158 deletant collection was screened to identify genes that are important for CQ resistance. 159
Preliminary experiments showed that 2.9 mM CQ was just sufficient to exert a mild 160 (∼10%) slowing on wild type growth, and this concentration was selected for screening. A 161 total of 97 CQ-sensitive strains (growth ratio ≥1.45) were identified from the genome-162 wide screen, and 23 of these phenotypes were subsequently confirmed in specific tests of 163 the 97 putative strains (see Table S1 in the supplemental material). The 23 deleted genes 164 of the sensitive strains were grouped into functional categories (24) and the resultant 165 distributions analyzed for significant differences compared with genome-wide distributions 166 for S. cerevisiae. 'Stress Response' was the most highly over-represented functional 167 category in the annotations of genes in the CQ sensitive dataset, owing to the sensitivity 168 of deletion strains including sat4Δ/sat4Δ, slt2Δ/slt2Δ and bck1Δ/bck1Δ ( Table 1 ). The 169 evident requirement for SLT2 and BCK1 in normal quinine resistance yielded additional 170 over-represented categories, including MAPKKK cascade and directional cell growth. 171
172
The CQ sensitivity of cell-wall integrity pathway mutants is bck1Δ-, slt2Δ-173 and drug-specific. Bck1p and Slt2p have key roles in the cell wall integrity pathway (25-174 27) . We conducted specific CQ-resistance tests with other mutants of the pathway. These 175
were not detected in the above screen (Table 1 ) but the screen criteria were stringent to 176 avoid false positives (6). Whereas the bck1Δ /bck1Δ and slt2Δ/slt2Δ mutants showed 177 marked growth defects versus wild type in the presence of CQ ( Fig. 1 
), any effects in other 178
Slt2 pathway mutants were slight (see Fig. S1A in the supplemental material). [Note that 179 particularly high CQ concentrations (>10 mM) were required in certain of these 180 experiments to overcome the CQ resistance of wild type S. cerevisiae; the relevant MICs 181 were ~20, 1.5 and 1.5 mM CQ for the wild type, bck1Δ/bck1Δ and slt2Δ/slt2Δ strains,respectively]. Similarly, deletion strains defective for cell surface sensors that signal to the 183 Slt2 pathway were not markedly CQ-sensitive (see Fig. S1B in the supplemental material). 184
There is some redundancy within the cell wall integrity pathway (25, 27) , and the results 185 indicate that it is a non-compensatable defect in the pathway (brought about only by BCK1 186 or SLT2 deletion) that is required to elicit the CQ sensitivity phenotype. 187
The effect of BCK1 or SLT2 deletion on drug sensitivity was tested with other 188 quinoline-containing antimalarials; quinine, mefloquine, amodiaquine and quinacrine. 189
Unlike CQ, none of these other drugs revealed a marked hypersensitivity phenotype of the 190 mutants versus wild type ( corroborate an involvement of cell wall integrity in CQ action, we tested the effects of 197 caffeine or CW on CQ resistance. The bck1Δ /bck1Δ and slt2Δ/slt2Δ mutants were 198 confirmed to be caffeine and CW hypersensitive ( Fig. 2A ). Consistent with cell wall damage 199 this sensitivity was rescued with 1 M sorbitol, and this was also the case for CQ ( Fig. 2A) . 200 CQ was supplied in combination with CW or caffeine at concentrations that were just sub-201 inhibitory to the relevant yeast strains when each drug was supplied alone. CW did not 202 cause hypersensitivity to CQ (Fig. 2B) . However, a combination of CQ and caffeine gave 203 markedly greater growth inhibition than the individual effects of the two drugs. This effect 204 was apparent in wild type, bck1Δ/bck1Δ and slt2Δ/slt2Δ strains. This indication of some 205 synergy in the effects of CQ and caffeine suggested that these drugs may have different 206 molecular targets, but their actions involve a common metabolic product or cell structure. 207
To substantiate that CQ action is related to cell wall integrity, cells were sonicated 208 during CQ exposure. Sonication physically weakens the yeast cell wall and makes it more 209 susceptible to the actions of chemical cell wall stressors (19). Wild type cells were cultured 210 with different sub-inhibitory concentrations of caffeine or CQ, then viability was 211 determined before and after sonication for 1 min in the presence of caffeine or CQ. In 212 controls where drugs were absent, the sonication treatment had negligible effect on 213 viability (Fig. 3) . However, in the presence of 4 mM caffeine or CQ, viability was decreased 214 ~80% by sonication. This was consistent with CQ action being related to cell wall integrity. 215 216 CQ toxicity is not mediated by effects on cell wall composition. We 217 considered two hypotheses to explain the above results: 1. The mode of CQ action against 218 yeast involves targeting of the cell wall, similar to CW and caffeine. 2. Cell wall integrity is 219 important for CQ resistance, possibly by preventing intracellular access of the drug. To 220
give clues to any specific cell wall components that may be affected by CQ (hypothesis 221 #1), first we conducted specific CQ resistance assays with 70 mutants defective for 222 biosynthesis of different cell wall components, including β-1,3 glucan, β-1,6 glucan, 223 mannoprotein and chitin. These mutants were not detected as CQ-sensitive in the screen 224 (see Table S1 in the supplemental material), nor did they prove to be CQ sensitive in our 225 specific assays (data not shown). This suggested that CQ does not target a particular cell 226 wall component. To corroborate this, we assayed each of the major cell wall components 227 of S. cerevisiae, exposed or not to CQ. The outcomes described below did not differ 228 whether cells were incubated for 3 h or overnight in the presence of CQ before cell wall 229 analysis. Aniline blue staining was used to indicate β-1,3 glucan content (21), which did 230 not differ significantly between CQ-exposed and non-exposed cells (see Fig. S2A in the 231 supplemental material). Similar results were obtained for the mannosylphosphate 232 component of cell wall mannoprotein (see Fig. S2B in the supplemental material), 233 according to alcian blue staining (22). However, using a sub-inhibitory concentration of 1.1 234 µM CW in order to stain chitin (23, 30) we noted a >1.5-fold increase in the apparent 235 chitin composition of the cell walls of CQ treated cells (Fig. 4A ) (p≤0.0002 at all CQconcentrations versus the CQ-free control). To test whether increased chitin content may 237 be a cause of CQ toxicity, a chitin-defective triple chitin synthase mutant YMS348s 238 (chs1Δ,chs2Δ,chs3Δ) was examined for CQ resistance. First it was confirmed that the 239 mutant was resistant to normally-inhibitory concentrations of CW (Fig. 4B) , consistent with 240 a mode of CW action involving binding to nascent chitin fibrils (31, 32). In contrast, the 241 YMS348s mutant exhibited similar CQ resistance as the isogenic wild type, indicating that 242 (increased) chitin is not an important mode of CQ action (Fig. 4B) . We confirmed that 243 there was no CQ-dependent increase in chitin content in the YMS348s mutant. 244
245
Cell wall perturbation facilitates CQ uptake into yeast cells. As the above 246 data did not support the hypothesis that CQ causes cell wall damage, we considered the 247 alternative hypothesis (#2) that cell wall integrity is required for normal CQ resistance. 248
Therefore, we performed sonication assays similar to those shown in Fig. 3 but where the 249 drug was removed just prior to sonication. We reasoned that if cell wall damage caused by 250 (prior) CQ exposure was the reason for sonication sensitivity (Fig. 3) , then cells should still 251 exhibit such sensitivity for some time after removing CQ. In contrast, the continued 252 presence of CQ would be required for sonication sensitivity if the relevant effect was to 253 enable CQ entry to the cell. In the case of caffeine as a positive control, viability was 254 decreased by ≥80% due to sonication whether 4 mM caffeine was retained (Fig. 3) or 255 removed just prior to sonication (Fig. 5A ) (sonication without any caffeine treatment had 256 negligible effect on viability). In contrast, cells were relatively resistant to sonication after 257 growth in up to 10 mM CQ when the drug was removed before sonication (Fig. 5B) , 258 whereas 4 mM CQ during sonication produces a ~80% loss of viability (Fig. 3) . These 259 outcomes for CQ were consistent with the hypothesis that normal cell wall integrity helps 260 to prevent CQ entry and its resultant toxicity in cells. To test that directly, uptake of the 261 drug was examined with a fluorescent probe approach (33). LynxTag-CQ uptake was 262 approximately two-fold and three-fold higher in the bck1Δ/bck1Δ and slt2Δ/slt2Δ mutants,respectively, than in wild type S. cerevisiae (Fig. 6A) . This was in keeping with these 264 mutants' CQ sensitivities. Similarly, other treatments used above to perturb the cell wall 265 (caffeine treatment and sonication) and which sensitized cells to CQ were also associated 266 with increased LynxTag-CQ uptake (Fig. 6B,C) . The results indicated that CQ toxicity is 267 greater in cell wall-perturbed cells due to increased CQ uptake. role for the mitogen-activated protein kinase (MAPK) cell wall integrity pathway (25) (26) (27) . 299
This was specific to CQ resistance, versus other closely related quinoline-containing 300 antimalarials. One structural difference between the drugs that may be pertinent here is 301 the occurrence of an aryl side chain in quinine, amodiaquine and mefloquine, whereas CQ 302 and quinacrine have an alkyl side chain (38). As quinacrine was the only drug tested other 303 than CQ where there was a suggestion of sensitivity in the bck1Δ/bck1Δ and slt2Δ/slt2Δ 304 mutants, the alkyl side chain may be one structural feature that helps determine this 305 phenotype. A key difference is that quinacrine has three fused aromatic rings, whereas CQ 306 has two rings. 307
Agents that target a component of the fungal cell wall typically cause altered levels 308 of that component. The content of other cell wall components is commonly modified in 309 compensation, to help sustain cell wall strength and integrity (39). The fact that mutants 310 for cell wall components were not CQ-hypersensitive was consistent with the cell wall not 311 being the primary target of CQ action. There were increases in chitin content of CQ 312 exposed cells, but chitin was not a target of CQ action as chitin synthase defective cells 313
were not affected for CQ resistance. This contrasted with calcofluor white which interferes 314 with chitin formation as its mode of action, and causes increased chitin synthase activity 315 (31, 32, 40, 41) . The increased chitin content seen with CQ appeared to be an incidentaleffect, consistent with the fact that the cell wall acts to help block CQ uptake rather than 317 be targeted by CQ action. 318
Little is known about the uptake of quinolone-containing drugs into yeast cells. 319
However, a mode of antifungal CQ action based on alkalinisation of the host environment 320 and iron deprivation has been proposed (12, 14, 15) cerevisiae. The lowest concentration at which a decrease in the MIC for caspofungin was 341 evident in vitro was 125 µM CQ. This concentration is higher than is typically encountered 342 in the clinical setting. In vivo concentrations in the plasma of patients treated with CQ arereported to be <5.9 µM (46). Furthermore, concentrations as low as 32 µM CQ are known 344 to cause growth inhibition in human cell lines (47). However, whereas the concentrations 345 used in this study were appropriate in vitro, a mode of antifungal CQ action that relies on 346 iron deprivation due to external alkalinisation (12, 14, 15) 
